Leerink Partners Boosts Aquestive Therapeutics (NASDAQ:AQST) Price Target to $13.00

Aquestive Therapeutics (NASDAQ:AQST) had its price target raised by Leerink Partners from $12.00 to $13.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other brokerages have also recently issued reports on AQST. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.83.

Aquestive Therapeutics Price Performance

Shares of AQST opened at $5.49 on Friday. The firm has a 50 day simple moving average of $4.77 and a two-hundred day simple moving average of $3.76. The company has a market cap of $499.80 million, a P/E ratio of -13.07 and a beta of 2.85. Aquestive Therapeutics has a one year low of $1.37 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the previous year, the firm posted ($0.10) EPS. On average, analysts expect that Aquestive Therapeutics will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new position in Aquestive Therapeutics during the second quarter worth $27,000. nVerses Capital LLC bought a new position in shares of Aquestive Therapeutics during the third quarter valued at about $28,000. SG Americas Securities LLC purchased a new position in Aquestive Therapeutics in the first quarter worth $54,000. The Manufacturers Life Insurance Company purchased a new position in Aquestive Therapeutics in the second quarter valued at about $76,000. Finally, Financial Advocates Investment Management grew its holdings in Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after purchasing an additional 14,000 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.